Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing ones. It plays a crucial role in various physiological and pathological conditions, including cancer. In cancer, angiogenesis is a rate-limiting critical step for tumour growth and cancer progression. Tumours require an adequate blood supply to receive oxygen, nutrients, and remove waste products. Initially, tumours rely on existing blood vessels in the surrounding tissue but as the tumour grows in mass it activates angiogenesis to form new blood vessels that directly supply the tumour. The process of angiogenesis involves several steps. First, the tumour cells release signalling molecules, such as vascular endothelial growth factor (VEGF), that stimulate nearby blood vessels to sprout new capillaries toward the tumour. This process of sprouting angiogenesis involves several sequential steps. Following VEGF activation, the extracellular matrix (ECM) and basement membrane surrounding the endothelial cells are degraded locally by proteases. Endothelial cells then invade into the surrounding matrix and proliferate and migrate through the matrix. By polarization of the migrating endothelial cells a lumen is created, and an immature blood vessel is formed. Once the endothelial cells reach the tumour, they proliferate and assemble into new blood vessels, a process called tubulogenesis. Finally, the newly formed blood vessels connect with the existing vasculature, allowing the tumour to establish a dedicated blood supply. Angiogenesis is crucial for cancer progression for several reasons. First, it provides oxygen and nutrients necessary for tumour cell survival and growth. Additionally, the newly formed blood vessels facilitate the spread of cancer cells to distant sites, a process known as metastasis. The formation of an extensive network of blood vessels also enables the tumour to evade the immune system, as it can create a barrier that limits immune cell infiltration. Understanding the critical role of angiogenesis in cancer has led to the development of anti-angiogenic therapies. These treatments aim to inhibit the formation of new blood vessels, thereby depriving the tumour of its blood supply and impeding its growth. Various drugs have been developed to target specific molecules involved in angiogenesis, such as VEGF and its receptors. By blocking these signals, anti-angiogenic therapies can help control tumour growth and improve patient outcomes. We offer a wide product catalogue of research reagents for studying angiogenesis, including Von Willebrand Factor antibodies, MMP9 antibodies, VEGF Receptor 2 antibodies, MMP9 ELISA Kits, and IL18 ELISA Kits. Explore our full angiogenesis product range below and discover more, for less. Alternatively, you can explore our Angiogenic Growth Factors, ECM Enzymes, and Angiogenic Inhibitory Factors product ranges.